Welcome
Pherecydes Pharma at a glance
Press Releases
Documentation
Documentation
Corporate Presentation
Financial report
Regulated information
Shares and voting rights
Liquidity contract
Share buyback programme
Directors’ disclosure
Financial operations
Shareholders
Shareholders
General Meeting
CSM of December 15, 2022
OGM of May 19, 2022
Shareholding structure
Financial calendar
Stock information
Analyst coverage
Strategic combination
Contacts
FR
EN
At the forefront of the fight
against bacterial infections
You are here:
Strategic combination
Strategic combination
02/17/2023 - 22:30
€1.5m capital increase reserved to the historical shareholders
02/16/2023 - 14:30
Presentation of the Strategic Combination Project
02/15/2023 - 22:40
ERYTECH and PHERECYDES Announce Proposed Combination Intending to Create Global Leader in Extended Phage Therapies
Z33333